Clinical Trials
20 trialsNCT04955743 2026-06-04
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
Yale University
Phase 2 Terminated
NCT07571551 2026-05-11
TRIPLE-PATH
Jinling Hospital, China
Phase 2 Recruiting
NCT05327686 2026-05-04
SAMURAI
NRG Oncology
Phase 2 Recruiting
NCT06138496 2026-04-21
Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Sun Yat-sen University
Phase 2 Completed
NCT04393350 2026-04-20
Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
Emory University
Phase 2 Active not recruiting
NCT05733715 2026-03-24
Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Recruiting
NCT07460206 2026-03-10
PRELUDE
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Not yet recruiting
NCT05012371 2026-03-05
Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06114940 2026-03-05
PLUTO
Jinling Hospital, China
Phase 2 Terminated
NCT07389629 2026-02-05
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Sun Yat-sen University
Phase 2 Recruiting
NCT07277972 2025-12-11
Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT05287464 2025-11-26
International Multicentric Study ARON-1
Hospital of Macerata
Recruiting
NCT07011849 2025-08-13
Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT03324373 2025-04-24
Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)
University of Iowa
Phase 1 Completed
NCT04267120 2025-03-21
Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)
Washington University School of Medicine
Phase 2 Terminated
NCT06364631 2025-01-16
CARE1
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT05188118 2024-11-06
Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
Icahn School of Medicine at Mount Sinai
Phase EARLY_PHASE1 Recruiting
NCT05485896 2024-09-19
Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC
Tianjin Medical University Second Hospital
Phase 2 Completed
NCT05949424 2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4 Unknown
NCT06129955 2023-11-13
Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma
Sun Yat-sen University
Phase 2 Unknown